Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial

Benzinga11-06

On Tuesday, Beam Therapeutics Inc. (NASDAQ:BEAM) announced that 35 patients have cleared screening and enrolled in the BEACON Phase 1/2 trial of BEAM-101, an investigational genetically modified cell ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481665305?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/KgvyaBCcO0Iui5akSUvg.A--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/c5166ea5608344d07a777635b697b99f","is_english":true,"pubTime":"2024-11-06 04:37","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481665305","market":"us","top_or_hot":-1,"title":"Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial","media":"Benzinga","content":"<div>\n<p>On Tuesday, Beam Therapeutics Inc. (NASDAQ:BEAM) announced that 35 patients have cleared screening and enrolled in the BEACON Phase 1/2 trial of BEAM-101, an investigational genetically modified cell ...</p>\n\n<a href=\"https://finance.yahoo.com/news/gene-therapy-developer-beam-therapeutics-203736331.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-06 04:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/gene-therapy-developer-beam-therapeutics-203736331.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On Tuesday, Beam Therapeutics Inc. (NASDAQ:BEAM) announced that 35 patients have cleared screening and enrolled in the BEACON Phase 1/2 trial of BEAM-101, an investigational genetically modified cell ...</p>\n\n<a href=\"https://finance.yahoo.com/news/gene-therapy-developer-beam-therapeutics-203736331.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4535","symbol_name":"淡马锡持仓","start_time":0,"source_url":"https://finance.yahoo.com/news/gene-therapy-developer-beam-therapeutics-203736331.html","article_id":"2481665305","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/KgvyaBCcO0Iui5akSUvg.A--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/c5166ea5608344d07a777635b697b99f"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481665305","pubTimestamp":1730839056,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"On Tuesday, Beam Therapeutics Inc.  announced that 35 patients have cleared screening and enrolled in the BEACON Phase 1/2 trial of BEAM-101, an investigational genetically modified cell therapy for sickle cell disease .Eight of these patients have been dosed with BEAM-101, while the other enrolled patients are going through pre-transplant stages, including cell collection and drug product manufacturing.In a company presentation, preliminary safety data (N=6) showed an initial safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant .The company said that one patient died due to respiratory failure likely related to busulfan conditioning 4 months after BEAM-101 infusion. However, the investigator determined that the death was unrelated to BEAM-101.In all patients dosed, there were no ≥ Grade 3 adverse events  or serious AEs related to BEAM-101.No vaso-occlusive crises  were reported by investigators following BEAM-101 tre","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4535":"淡马锡持仓","SSI":"Stage Stores Inc","BEAM":"Beam Therapeutics, Inc.","BK4556":"基因编辑","SCD":"LMP Capital & Income Fund","BK4505":"高瓴资本持仓","HSCT":"HOOPS SCOUTING USA","BK4139":"生物科技","BK4585":"ETF&股票定投概念","BK4588":"碎股","LENZ":"Therapeutics"},"translate_title":"基因疗法开发商Beam Therapeutics报告早期镰状细胞病试验中一名患者死亡","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HSCT":1,"LENZ":1,"SCD":1,"SSI":1,"BEAM":0.9},"content_text":"On Tuesday, Beam Therapeutics Inc. (NASDAQ:BEAM) announced that 35 patients have cleared screening and enrolled in the BEACON Phase 1/2 trial of BEAM-101, an investigational genetically modified cell therapy for sickle cell disease (SCD).\nEight of these patients have been dosed with BEAM-101, while the other enrolled patients are going through pre-transplant stages, including cell collection and drug product manufacturing.\nAlso Read: Gene Editing Korro Bio’s Preclinical Data ‘Best-In-Class’, Analyst Initiates With Outperform Rating\nIn a company presentation, preliminary safety data (N=6) showed an initial safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant (HSCT).\nThe company said that one patient died due to respiratory failure likely related to busulfan conditioning 4 months after BEAM-101 infusion. However, the investigator determined that the death was unrelated to BEAM-101.\nThe Data Safety Monitoring Committee and FDA reviewed the case.\nIn all patients dosed, there were no ≥ Grade 3 adverse events (AEs) or serious AEs related to BEAM-101.\nPreliminary efficacy data showed that all patients achieved over 60% fetal hemoglobin (HbF, the main oxygen carrier protein in the human fetus) and less than 40% HbS (an abnormal type of hemoglobin that causes sickle cell disease) of non-transfused hemoglobin at Month 1, sustained through all time points.\nMarkers of hemolysis (destruction of red blood cells) normalized or improved for all patients.\nNo vaso-occlusive crises (VOCs, painful complication of sickle cell anemia) were reported by investigators following BEAM-101 treatment.\nBeam Therapeutics said patient enrollment in the Phase 1/2 trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency (AATD) is progressing. Site activation globally has continued, and dosing has been completed for the first cohort.\nBeam has nominated a development candidate for its ESCAPE technology comprised of two investigational drug products: BEAM-103, an anti-CD117 monoclonal antibody (mAb), and BEAM-104, a cell therapy that includes the same therapeutic edit as BEAM-101 (editing the HBG1/2 genes to elevate fetal hemoglobin), plus an additional edit to CD117 which is designed to prevent binding of BEAM-103, allowing the edited cells to evade suppression by the antibody.\nThe company intends to advance BEAM-103 and BEAM-104 for development in SCD and beta-thalassemia.\nBeam Therapeutics ended the third quarter of 2024 with $925.8 million in cash, cash equivalents, and marketable securities, providing a cash runway into 2027.\nPrice Action: BEAM stock is down 2.40% at $23.78 at the last check on Tuesday.\nRead Next:\n\nNvidia Takes Short-Lived Lead Over Apple In Valuation\n\nUNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.\nGet the latest stock analysis from Benzinga?\n\nBEAM THERAPEUTICS (BEAM): Free Stock Analysis Report\n\nThis article Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial originally appeared on Benzinga.com\n© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481665305"}